Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Revenues up on Higher-Than-Expected Product Sales

NEW YORK, May 14 - Third Wave Technologies of Madison, Wis., reported first-quarter 2001 revenues of $11.2 million Monday, up from $0.6 million for the same quarter in 2000. 

The company attributed the jump in revenues to increased sales of its Cleavase enzyme and Invader Operating System tests and reagents, which were several million dollars above expectations, the company said. Product sales for the quarter ended March 31, 2001, were $10.2 million, up from $0.6 million in the same period of 2000. 

Total operating expenses increased to $17.7 million for the quarter, from $5.1 million for the same period in 2000, due to large-scale expansion of commercialization activities and a higher cost of goods sold than expected, Third Wave said. 

The company reported a net loss of $5.9 million for the quarter, or 20 cents per diluted share, compared to a net loss of $4.3 million, or 29 cents per diluted share for the year-ago period. On a pro-forma basis the first-quarter 2001 net loss was 16 cents per share, compared to 18 cents per share for same period in 2000. 

"We are very pleased with our first quarter performance," Third Wave CEO Lance Fors said in a statement. "We have manufactured and shipped over 40,000 unique Invader genotyping assays from Q3 of 2000 through Q1 of 2001…We believe these results demonstrate that Third Wave's Invader technology is the emerging operating system for DNA analysis for research and clinical applications."

In February, Third Wave completed its IPO of 7.5 million shares, raising $82.5 million. 

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.